Home Drug IndexClinical Monograph

Botulinum Toxin A Injection – Uses, Dosage, Side Effects, Cost | DrugsAtlas

Authoritative Clinical Reference

Neuromuscular blocking agent

DRUG NAME: Botulinum Toxin A

Therapeutic Class:

Neurotoxin

Subclass:

Neuromuscular Blocking Agent

Schedule (India):

Schedule H

Routes

Intramuscular, Intradermal, Intravesical (specialist only)

Formulations Available in India

Injection: 100 units/vial (lyophilised powder for reconstitution)

Injection: 200 units/vial (lyophilised powder for reconstitution)

Injection: 300 units/vial (Dysport — units not interchangeable)

Injection: 500 units/vial (Dysport — units not interchangeable)

Note: Units are NOT interchangeable between brands. Botox/Xeomin units differ from Dysport units. Dosing must follow product-specific guidelines.

ADULT INDICATIONS

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ 1. Cervical Dystonia (Spasmodic Torticollis) — Adults

Parameter	Recommendation
Starting dose	120–200 units total, divided among affected neck muscles (sternocleidomastoid, splenius capitis, trapezius, levator scapulae)
Titration	Adjust based on clinical response and muscle mass; increase by 50–100 units per cycle if inadequate response
Usual maintenance dose	150–300 units per session every 12–16 weeks
Maximum dose	400 units per session

Clinical Notes:

EMG or ultrasound guidance recommended for precise muscle localisation
Response typically begins within 2 weeks; peak effect at 4–6 weeks
Do not re-inject before 12 weeks

▶ 2. Blepharospasm and Hemifacial Spasm — Adults

Parameter	Recommendation
Starting dose	1.25–2.5 units per injection site into orbicularis oculi; total 12–25 units per eye
Titration	Increase by 1.25 units per site based on response
Usual maintenance dose	25–50 units total (both eyes) every 12–16 weeks
Maximum dose	100 units per session (both eyes combined)

Clinical Notes:

Inject medially into orbicularis to reduce ptosis risk
Avoid injection near levator palpebrae superioris

▶ 3. Strabismus — Adults

Parameter	Recommendation
Starting dose	1.25–2.5 units for vertical muscles and small deviations; 2.5–5 units for horizontal rectus muscles
Titration	Re-inject after 7–14 days if initial response inadequate
Usual maintenance dose	2.5–5 units per muscle
Maximum dose	25 units per muscle per session

Clinical Notes:

EMG guidance mandatory
Specialist ophthalmologist administration only

▶ 4. Post-Stroke Upper Limb Spasticity — Adults

Parameter	Recommendation
Starting dose	75–150 units total, distributed across affected muscles (biceps, flexor carpi radialis/ulnaris, finger flexors)
Titration	Increase by 50–100 units per cycle based on Modified Ashworth Scale improvement
Usual maintenance dose	200–300 units per session every 12–16 weeks
Maximum dose	400 units per session across all upper limb muscles

Clinical Notes:

Combine with physiotherapy for optimal functional outcomes
Ultrasound-guided injection improves accuracy
Document baseline spasticity scores for monitoring

▶ 5. Overactive Bladder (Idiopathic) — Adults

Parameter	Recommendation
Starting dose	100 units intravesically, distributed across 20 injection sites in detrusor muscle
Titration	Not applicable
Usual maintenance dose	100 units per session
Maximum dose	100 units per session; re-injection not before 12 weeks

Clinical Notes:

Cystoscopic administration under local/general anaesthesia
Post-void residual monitoring mandatory
Patient must be willing to self-catheterise if retention occurs

▶ 6. Neurogenic Detrusor Overactivity — Adults (Specialist Only)

Parameter	Recommendation
Starting dose	200 units intravesically, distributed across 30 injection sites
Titration	Reduce to 100 units if excessive weakness or retention
Usual maintenance dose	200 units per session every 12–16 weeks
Maximum dose	200 units per session

Clinical Notes:

Associated with spinal cord injury, multiple sclerosis
Higher retention risk; ensure catheterisation capability

▶ 7. Chronic Migraine Prophylaxis — Adults (Specialist Only)

Parameter	Recommendation
Starting dose	155 units total, divided across 31 injection sites (frontalis, corrugator, procerus, occipitalis, temporalis, trapezius, cervical paraspinals)
Titration	May increase to 195 units across 39 sites if additional trigger areas identified
Usual maintenance dose	155–195 units every 12 weeks
Maximum dose	195 units per session

Clinical Notes:

Only for chronic migraine (≥15 headache days/month for ≥3 months, with ≥8 migraine days)
Assess efficacy after 2 treatment cycles (24 weeks)
Not indicated for episodic migraine

▶ 8. Primary Axillary Hyperhidrosis — Adults

Parameter	Recommendation
Starting dose	50 units per axilla (100 units total), intradermal injection
Titration	Not typically required
Usual maintenance dose	50 units per axilla every 6–9 months
Maximum dose	100 units per axilla per session

Clinical Notes:

Perform Minor’s starch-iodine test to map hyperhidrotic area
Multiple intradermal injections spaced 1–2 cm apart

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Notes
Sialorrhoea (Parkinson’s disease, ALS)	30–100 units total divided between parotid (20–30 units each) and submandibular glands (10–15 units each)	Re-inject every 3–4 months	OFF-LABEL; Ultrasound-guided; Specialist only; Supported by RCTs (Lagalla et al., Neurology India practice)
Bruxism	20–30 units per masseter muscle bilaterally (total 40–60 units)	Re-inject every 3–6 months	OFF-LABEL; Specialist only; Case series evidence
Anal Fissure (chronic)	20–40 units into internal anal sphincter	Single injection; may repeat after 3 months	OFF-LABEL; Specialist only; Used in Indian surgical practice

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

▶ 1. Cerebral Palsy — Limb Spasticity

Age Group	Starting Dose	Titration	Maximum Dose
≥2 years	1–2 units/kg per muscle group	Increase by 1 unit/kg per cycle based on response	Lower of: 300 units total OR 12 units/kg per session
Adolescents (≥12 years)	2–6 units/kg per muscle group	As per adult principles	400 units per session

Muscle-Specific Guidance:

Gastrocnemius/soleus: 3–6 units/kg per leg
Hamstrings: 2–4 units/kg per leg
Adductors: 2–4 units/kg per leg

Clinical Notes:

Repeat every 12–16 weeks
Combine with physiotherapy, orthoses, serial casting
Monitor for generalised weakness

▶ 2. Paediatric Strabismus (≥12 months)

Age	Starting Dose	Maximum Dose
12–24 months	1.25 units per muscle	2.5 units per muscle
>2 years	1.25–2.5 units for small deviations; up to 5 units for larger	25 units per muscle

Clinical Notes:

EMG-guided injection mandatory
Specialist paediatric ophthalmologist only
Re-injection after 3–6 months if needed

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Notes
Neurogenic Detrusor Overactivity (spina bifida)	5–10 units/kg intravesically (max 200 units)	Re-inject every 6–9 months	OFF-LABEL; Under general anaesthesia; Specialist only; Used in Indian tertiary centres (AIIMS protocols)

Age Restriction Statement:

Not recommended below 2 years of age except under specialist supervision in tertiary centres
Below 12 months: Only in exceptional circumstances with paediatric neurology/rehabilitation input

Safety Monitoring:

Post-injection observation for 2–4 hours
Monitor for dysphagia, respiratory difficulty, generalised weakness
Ensure caregiver awareness of warning signs

RENAL ADJUSTMENT

No dose adjustment required
Botulinum toxin acts locally at neuromuscular junction; negligible systemic absorption
General caution in frail patients with multiple comorbidities

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No dose adjustment required
Moderate impairment	No dose adjustment required
Severe impairment	No specific data; use with caution under specialist supervision

CONTRAINDICATIONS

Known hypersensitivity to botulinum toxin type A or formulation excipients (human albumin, sucrose)
Infection at proposed injection site
Generalised disorders of neuromuscular transmission (myasthenia gravis, Lambert-Eaton myasthenic syndrome)
Coexisting therapy with aminoglycosides at time of planned injection (postpone botulinum)
Pregnancy (Category C — avoid unless absolutely necessary)

CAUTIONS

Pre-existing swallowing or breathing difficulties — increased aspiration risk with cervical/bulbar injections
History of aspiration pneumonia
Patients on anticoagulants — increased bruising risk; hold if feasible
Neuromuscular disorders (motor neurone disease, peripheral neuropathies) — unpredictable response
Previous non-response to botulinum toxin — consider neutralising antibodies
High cumulative doses over time — antibody formation risk
Elderly and frail patients — enhanced sensitivity
Children <2 years — very limited safety data

PREGNANCY

Parameter	Recommendation
Risk Category	Category C — Avoid unless clearly necessary
Safety Data	Animal studies show developmental toxicity; no adequate human data
Preferred Alternatives	Physiotherapy, oral baclofen (with caution), conservative management
When May Be Used	Only for severe, debilitating dystonia when no alternatives exist; specialist decision
Monitoring	Fetal well-being via ultrasound if administered in 2nd/3rd trimester

LACTATION

Parameter	Recommendation
Compatibility	Likely compatible due to large molecular size and local action
Expected Levels in Milk	Negligible — systemic absorption minimal
Preferred Alternatives	None specifically; may continue breastfeeding
Infant Monitoring	Feeding difficulty, hypotonia, poor weight gain (unlikely but monitor)
Recommendation	Avoid unless essential; if used, short-term breastfeeding interruption not mandatory

ELDERLY

Parameter	Recommendation
Starting Dose	Use lower end of dose range (reduce by 20–30% from standard adult)
Titration	Slower titration; extend interval between sessions if needed
Extra Risks	Increased sensitivity to neuromuscular effects; dysphagia risk with cervical injections; falls risk; aspiration pneumonia
Monitoring	Close observation for 48 hours post-injection; assess swallowing before discharge

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect	Management
Aminoglycosides (gentamicin, amikacin, streptomycin)	Potentiate neuromuscular blockade; risk of respiratory compromise	Avoid concurrent use; delay botulinum if aminoglycoside therapy ongoing
Non-depolarising muscle relaxants (vecuronium, atracurium)	Additive neuromuscular blockade	Avoid elective procedures requiring NMBAs within 2–4 weeks of botulinum
Other botulinum toxin products	Cumulative toxicity; unpredictable blockade	Do not administer different botulinum products concurrently
Spectinomycin, polymyxins	Potentiate neuromuscular blockade	Avoid combination

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Management
Anticholinergics (oxybutynin, tolterodine)	Additive anticholinergic effects; urinary retention risk with intravesical use	Monitor for retention; avoid combination in bladder indications unless specialist supervised
Anticoagulants/Antiplatelets (warfarin, aspirin, clopidogrel)	Increased bruising at injection sites	Consider temporary hold if feasible; apply pressure post-injection
Quinidine	May potentiate neuromuscular effects	Use with caution; monitor for weakness
Magnesium sulphate	Potentiates neuromuscular blockade	Caution in eclampsia management if botulinum recently administered
Benzodiazepines	Additive muscle weakness	Use cautiously in elderly; monitor for falls

COMMON ADVERSE EFFECTS

Injection site pain, erythema, bruising
Localised muscle weakness (intended effect may extend beyond target)
Headache (particularly with migraine prophylaxis indication)
Ptosis (with periocular injections)
Dysphagia (with cervical/neck injections; 10–20%)
Dry mouth (with sialorrhoea or hyperhidrosis treatment)
Flu-like symptoms
Fatigue

SERIOUS ADVERSE EFFECTS

Generalised muscle weakness — rare; may be life-threatening; requires immediate medical attention
Respiratory compromise/failure — especially with high doses or pre-existing respiratory conditions
Aspiration pneumonia — secondary to dysphagia; higher risk in elderly and those with bulbar dysfunction
Anaphylaxis — rare; discontinue and treat as emergency
Distant spread of toxin effect — weakness in muscles remote from injection site; Black Box Warning equivalent
Urinary retention — with intravesical use; may require catheterisation

Action: Discontinue immediately and provide supportive care if generalised weakness or respiratory compromise suspected.

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Neuromuscular function assessment; document severity scores (Modified Ashworth Scale for spasticity, TWSTRS for cervical dystonia); swallowing assessment if cervical injection planned
Post-injection (48–72 hours)	Observe for dysphagia, respiratory difficulty, generalised weakness; advise patient/caregiver on warning signs
Short-term (2–4 weeks)	Assess clinical response; document improvement
Long-term	Re-evaluate efficacy every 3–4 months; monitor for development of neutralising antibodies (reduced efficacy over time); reassess benefit-risk at each cycle

BRANDS AVAILABLE IN INDIA

BOTOX® (Allergan/AbbVie) — 100 units, 200 units/vial
Xeomin® (Merz Pharma) — 100 units/vial
Dysport® (Ipsen) — 300 units, 500 units/vial (Note: Dysport units NOT interchangeable with Botox/Xeomin)

PRICE RANGE (INR)

Brand	Strength	Approximate Price
BOTOX®	100 units	₹14,000–18,000 per vial
BOTOX®	200 units	₹26,000–32,000 per vial
Xeomin®	100 units	₹10,000–14,000 per vial
Dysport®	500 units	₹20,000–28,000 per vial

Not included in NLEM; not under NPPA price control
Available in tertiary hospitals through institutional procurement at lower rates
Private sector pricing variable

CLINICAL PEARLS

Unit non-interchangeability is critical — Botox/Xeomin units differ from Dysport; approximately 2.5–3 Dysport units ≈ 1 Botox unit (not exact; follow product-specific dosing)
Reconstitution — Use preservative-free 0.9% saline only; use within 4 hours of reconstitution (24 hours if refrigerated for some products)
Injection technique — EMG or ultrasound guidance significantly improves outcomes in deep muscles; mandatory for strabismus and recommended for spasticity
Resistance management — If efficacy wanes, consider neutralising antibodies; minimise total dose per session and maximise inter-injection intervals; switching brands may help in some cases
Patient counselling — Effect onset in 3–7 days; peak at 2–4 weeks; duration 3–4 months; set realistic expectations
Post-injection care — Avoid rubbing injection site; remain upright for 4 hours post-facial injection to prevent toxin spread

VERSION

RxIndia v0.2 — 03 Feb 2026

REFERENCES

CDSCO approved product inserts (Allergan BOTOX®, Xeomin®, Dysport® India)
Indian Pharmacopoeia
AIIMS Drug Formulary — Neurology & Paediatric Neurology Departments
Neurology Society of India clinical practice recommendations
Indian Urological Society guidelines (intravesical use)
API Textbook of Medicine
Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
NFI 2021
RCT evidence (sialorrhoea, chronic migraine — for off-label indications only)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...